Sign up to save your podcasts
Or
Share One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
Despite this, GRAIL has been doggedly positive in its press about the results.
In this episode of The Cancer Letter Podcast, GRAIL’s vice president of Medical and Corporate Affairs, Megan Hall, says that GRAIL is “really excited about it, despite the missed primary endpoint, and we’re excited enough that we announced publicly that we’re expanding our sales and medical teams in response to this, because we expect that when we’re able to talk about the data much more fulsomely, that there will also be some excitement about this.
“We are confident that [Galleri] is showing clinical benefit,” Hall said.
The company says it will submit the full data for presentation at ASCO in late May and early June.
Multi-cancer detection screening has been a hot button topic for the field, and interested readers can dive into a comprehensive story about the trial results in last week's issue. But for this podcast, we decided to feature GRAIL’s perspective directly alongside NCI’s.
First, Megan Hall explains why GRAIL is excited about the results of the negative study. Then, Philip Castle, director of NCI's Division of Cancer Prevention, laments the trial’s unfortunate result.
This episode of The Cancer Letter Podcast was sponsored by City of Hope. Learn more at http://www.cityofhope.org.
Stories mentioned in this podcast include:
GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ
NCI's Philip Castle on NHS-Galleri results: “I'm sorry that it didn't work, but it keeps the national conversation going.”
Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68
Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
A transcript of this podcast is available: https://cancerletter.com/podcastc/20260311-nhs-galleri/
View all episodes
By The Cancer LetterOn Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
Despite this, GRAIL has been doggedly positive in its press about the results.
In this episode of The Cancer Letter Podcast, GRAIL’s vice president of Medical and Corporate Affairs, Megan Hall, says that GRAIL is “really excited about it, despite the missed primary endpoint, and we’re excited enough that we announced publicly that we’re expanding our sales and medical teams in response to this, because we expect that when we’re able to talk about the data much more fulsomely, that there will also be some excitement about this.
“We are confident that [Galleri] is showing clinical benefit,” Hall said.
The company says it will submit the full data for presentation at ASCO in late May and early June.
Multi-cancer detection screening has been a hot button topic for the field, and interested readers can dive into a comprehensive story about the trial results in last week's issue. But for this podcast, we decided to feature GRAIL’s perspective directly alongside NCI’s.
First, Megan Hall explains why GRAIL is excited about the results of the negative study. Then, Philip Castle, director of NCI's Division of Cancer Prevention, laments the trial’s unfortunate result.
This episode of The Cancer Letter Podcast was sponsored by City of Hope. Learn more at http://www.cityofhope.org.
Stories mentioned in this podcast include:
GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.” Mainstream epidemiologists beg to differ
NCI's Philip Castle on NHS-Galleri results: “I'm sorry that it didn't work, but it keeps the national conversation going.”
Erin Cummings, Cancer Nation advocate, dies of stomach cancer at 68
Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
A transcript of this podcast is available: https://cancerletter.com/podcastc/20260311-nhs-galleri/